Impaired brachial artery endothelial function is not predicted by elevated triglycerides

Schnell, Gregory; Robertson, Annette; Houston, David C.; Malley, L. K.; Anderson, Todd J.

doi:10.1016/s0735-1097(99)00104-7

Cited by 52 publications

(33 citation statements)

References 44 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…39 Several studies have examined the effects of hypertriglyceridaemia on vasomotor function of peripheral vessels, with inconsistent results. [39][40][41] Triglyceride levels were related to generalised arteriolar narrowing in the ARIC study (P ¼ 0.012) 13 and retinopathy in the Hoorn Study, 15 but not related to any retinal microvascular signs neither in the CHS 14 nor in our study. However, we found a U-shaped relationship between triglyceride levels and retinal venular diameter in the current study.…”

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

Dyslipidaemia and microvascular disease in the retina

Leung

Wang

Rochtchina

et al. 2004

Eye

View full text Add to dashboard Cite

Purpose There are few data on the effect of serum lipids on microvascular disease. This study assessed the relationships between serum lipid levels and microvascular disease, as seen in the retina, among participants who attended a population-based study in Australia (n ¼ 3654, aged 49 þ years). Methods Diameters of retinal arterioles and venules were measured from digitised photographs of each participant to obtain an estimate of generalised arteriolar narrowing. Focal arteriolar narrowing, arteriovenous nicking, and retinopathy lesions (microaneurysms, haemorrhages, hard/soft exudates) were graded using a standard protocol. Fasting blood tests were performed in 89% of subjects. Adjusted means were calculated using general linear models. Logistic regression models were used to determine the odds ratios for retinal microvascular signs. Results After controlling for age, sex, body mass index, smoking, and mean arterial blood pressure, elevated high-density lipoprotein cholesterol was associated with narrower retinal arterioles (P trend ¼ 0.002) and venules (P trend ¼ 0.03) and with increased odds of generalised arteriolar narrowing (odds ratio 1.6, 95% confidence interval 1.1-2.2 for the highest vs the lowest quintile of high-density lipoprotein cholesterol). Serum triglyceride had a U-shaped relationship with venular diameter (P trend ¼ 0.003). We found no consistent pattern of association between serum total cholesterol or low-density lipoprotein cholesterol and any retinal microvascular signs. Conclusions These findings suggest that microvascular disease in the retina may result from processes distinct from dyslipidaemia.

show abstract

Section: Discussionmentioning

confidence: 99%

“…Another limitation was the use of Freidwald equation to calculate LDL cholesterol levels. Such calculation was suggested to be inaccurate when triglyceride levels are higher than 5 mmol/l, 39 resulting in a possible systematic error among hypertriglyceridaemic subjects.…”

Section: Discussionmentioning

confidence: 99%

Dyslipidaemia and microvascular disease in the retina

Leung

Wang

Rochtchina

et al. 2004

Eye

View full text Add to dashboard Cite

show abstract

“…21 Lewis et al 22 compared obese hypertriglyceridemic (serum triglycerides 7.0 mmol/L) subjects with lean normotriglyceridemic subjects, Chowienczyk et al 20 studied subjects with lipoprotein lipase deficiency resulting in chylomicronemia and total triglycerides of Ϸ20 mmol/L, and Schnell et al 21 compared subjects with mean serum triglycerides of 4.2 mmol/L with subjects with hypercholesterolemia and normolipemic control subjects. The results were contradictory.…”

Section: Vakkilainen Et Al Small Ldl and Endothelial Dysfunction 719mentioning

confidence: 99%

“…[17][18][19] Although increased LDL cholesterol concentrations have consistently been associated with endothelial dysfunction, it is controversial whether individuals with hypertriglyceridemia and normal or low LDL cholesterol concentrations have impaired endothelial function. Two studies found endothelial function to be normal 20,21 and 1 study abnormal 22 in hypertriglyceridemic subjects. The latter study compared obese hypertriglyceridemic subjects with normal-weight normotriglyceridemic subjects, and it remained unclear whether obesity or hypertriglyceridemia explained endothelial dysfunction.…”

mentioning

confidence: 99%

Endothelial Dysfunction in Men With Small LDL Particles

et al. 2000

View full text Add to dashboard Cite

Background-It is unknown whether LDL particle size is, independent of other lipids and lipoproteins, associated with endothelial dysfunction in vivo. Methods and Results-We determined in vivo endothelial function in 34 healthy men by measuring forearm blood flow responses to intrabrachial artery infusions of acetylcholine (ACh, an endothelium-dependent vasodilator) and sodium nitroprusside (an endothelium-independent vasodilator). LDL peak particle size was measured with gradient gel electrophoresis. Men with small LDL particles (LDL diameter Յ25.5 nm, nϭ10) had a 39% lower blood flow response to ACh than men with large LDL particles (LDL diameter Ͼ25.5 nm, nϭ24, blood flow 6.9Ϯ3.6 versus 11.4Ϯ5.1 mL/dL ⅐ min, Pϭ0.006).

show abstract

“…There is evidence suggesting that endothelial function is impaired in patients with elevated levels of plasma triglycerides [15][16][17], although this finding was not universally confirmed [18].…”

Section: Introductionmentioning

confidence: 99%

Fibrate therapy and flow-mediated dilation: A systematic review and meta-analysis of randomized placebo-controlled trials

Sahebkar

Giua

Pedone

et al. 2016

Pharmacological Research

View full text Add to dashboard Cite

Flow-mediated dilation (FMD) of the brachial artery reflects endothelium-dependent vasodilator function; since it correlates with coronary endothelial function, its reduction could predict cardiovascular events. Several studies have investigated the potential impact of fibrates therapy on endothelial function, but clinical findings have not been fully consistent. We aimed to conduct a meta-analysis of randomized placebo-controlled trials in order to clarify whether fibrate therapy could improve endothelial function. A systematic search in PubMed-Medline, SCOPUS, Web of Science and Google Scholar databases was performed to identify randomized placebo-controlled trials investigating the effect of fibrates on endothelial function as estimated by FMD. A randomeffects model and generic inverse variance method were used for meta-analysis. Sensitivity analysis, risk of bias evaluation, and publication bias assessment were carried out using standard methods. Random-effects meta-regression was used to evaluate the impact of treatment duration on the estimated effect size. Fifteen trials with a total of 556 subjects met the eligibility criteria. Fibrate 3 therapy significantly improves FMD (weighted mean difference [WMD]: 1.64%, 95% CI: 1.15, 2.13, p < 0.001) and the result was confirmed in both subgroups with treatment durations ≤8 weeks (WMD: 1.35%, 95% CI: 0.85, 1.86, p < 0.001) and >8 weeks (WMD: 2.55%, 95% CI: 1.21, 3.89, p < 0.001). When the analysis was stratified according to the fibrate type, a significant effect was observed with fenofibrate but not with gemfibrozil, though difference between the two subgroups was not significant. Meta-analysis of data from trials where nitrate mediated dilation (NMD) was available did not suggest a significant change in NMD following treatment with fibrates. The results of this meta-analysis suggest that fibrates may exert beneficial effects on endothelial function, even over a short-term treatment course.

show abstract

Impaired brachial artery endothelial function is not predicted by elevated triglycerides

Cited by 52 publications

References 44 publications

Dyslipidaemia and microvascular disease in the retina

Dyslipidaemia and microvascular disease in the retina

Endothelial Dysfunction in Men With Small LDL Particles

Fibrate therapy and flow-mediated dilation: A systematic review and meta-analysis of randomized placebo-controlled trials

Contact Info

Product

Resources

About